BASF's Evonik Ambitions Meet a Double Reality Check
Published on 11/19/2026 at 02:51 | Editorial boerse-global.deBASF shareholders have two very different stories to digest this week, and they point in the same uncomfortable direction: the chemicals group is spending heavily on its own future without yet proving that the spending will pay off. On the trading floor, the stock slipped 1.6% to €51.30 on Monday after Jefferies cut its recommendation from "Hold" to "Underperform" on 11 November, leaving the price target untouched at €44.
The downgrade landed alongside news that BASF had bought back roughly 8.54 million of its own shares between 3 August and 13 November inclusive, with about 591,000 of those repurchased in the 9–13 November window alone. A company confident in its own valuation does not usually need to lean this hard on buybacks — and Jefferies, for one, is not convinced.
A Mining Exit and a Fresh Evonik Push
On the dealmaking front, BASF signed an agreement on 12 November to sell its mining business to SNF, with completion expected in 2027 subject to regulatory clearances and customary closing conditions. Alongside that disposal, Reuters reports that BASF is preparing another attempt to acquire Evonik, though no new offer has been confirmed. The group has reportedly sketched out possible additional commitments on sites, jobs and apprenticeships to the North Rhine-Westphalia state government and the RAG-Stiftung.
That charm offensive ran straight into political resistance. Minister-President Hendrik Wüst came out against a BASF takeover of Evonik, telling the Süddeutsche Zeitung that the industrial core of North Rhine-Westphalia should be preserved. His economy minister, Mona Neubaur, has likewise rejected the deal, pointing to Evonik's own strategy.
Should investors sell immediately? Or is it worth buying BASF?
Why a Bigger Cheque Isn't the Answer
For BASF investors, the central question is not whether a fresh bid tops the last one. Evonik has already turned down two approaches, the most recent at €24 per share — valuing the equity at around €11.2 billion. The Handelsblatt, citing financial circles, floats a possible range of €26 to €28 per Evonik share for a new offer, though that is no confirmed price. Bloomberg reported that BASF is courting state politicians, MPs and the RAG-Stiftung for support, while Reuters notes Evonik could reject an even higher bid. A richer price tag, on its own, would be no signal that a deal is any closer.
What Evonik wants, according to Reuters, is a recognisable industrial logic. That test cuts both ways: whatever persuades Evonik to talk must also explain why BASF should commit more capital to the combination. Pledges on individual sites may soothe local concerns, but they do not answer the bigger question of what the two companies gain together that they could not achieve pursuing their separate plans.
The Sticking Points: Jobs, Sites and €5 Billion
A favourable outcome for BASF would require a new offer that pairs industrial rationale with concrete answers on the plants. BASF has said it will honour existing employee agreements, keep the Marl and Wesseling chemical parks running and preserve Essen as a key site. Bloomberg reports that further job and investment guarantees in the Ruhr region are planned, though the size of the investments and the length of any ban on compulsory redundancies remain open.
Evonik, for its part, points to job protection through the end of 2032 and investment commitments of roughly €5 billion for German sites. Any pledge to the workforce would be measured against what it adds beyond those existing assurances. Bloomberg also indicates Evonik is open to an informal meeting — a chance to scrutinise the industrial case and the proposed commitments, though willingness to talk is not consent to a takeover.
The Calendar's Next Marker
The next fixed date is the meeting of the RAG-Stiftung's board of trustees on 25 November. The foundation holds around 43% of Evonik and is among the parties BASF is courting. Media reports suggest a new offer could arrive before that gathering, though whether BASF tables one in time — and whether the trustees take a position on a takeover — remains uncertain.
The downside risk is plain: BASF could raise its price and sweeten its commitments without ever clearing Evonik's objections. Until Evonik sees a sufficient industrial reason to negotiate, a higher bid mostly means more capital deployed. Should Evonik shift its stance on the back of a concrete concept, the prospect of talks would merit a fresh look — but even then, what matters for the BASF share is not the chance of a deal, but the total price the group is prepared to pay for it.
Ad
BASF Stock: New Analysis - 19 November
Fresh BASF information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
